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Abstract
The cholinergic neurotransmitter system is critically linked to cognitive functions including
attention. The current studies were designed to evaluate the effect of a cholinergic agonist and an
antagonist on performance during a selective visual attention task where the inherent salience of
attended/unattended stimuli was modulated. Two randomized, placebo-controlled, crossover
studies were performed, one (n = 9) with the anticholinesterase physostigmine (1.0 mg/h), and the
other (n = 30) with the anticholinergic scopolamine (0.4 mc/kg). During the task, two double-
exposure pictures of faces and houses were presented side by side. Subjects were cued to attend to
either the face or the house component of the stimuli, and were instructed to perform a matching
task with the two exemplars from the attended category. The cue changed every 4–7 trials to
instruct subjects to shift attention from one stimulus component to the other. During placebo in
both studies, reaction time (RT) associated with the first trial following a cued shift in attention
was longer than RT associated with later trials (p<0.05); RT also was significantly longer when
attending to houses than to faces (p<0.05). Physostigmine decreased RT relative to placebo
preferentially during trials greater than one (p<0.05), with no change during trial one; and
decreased RT preferentially during the attention to houses condition (p<0.05) vs attention to faces.
Scopolamine increased RT relative to placebo selectively during trials greater than one (p<0.05),
and preferentially increased RT during the attention to faces condition (p<0.05). The results
suggest that enhancement or impairment of cholinergic activity preferentially influences the
maintenance of selective attention (ie trials greater than 1). Moreover, effects of cholinergic
manipulation depend on the selective attention condition (ie faces vs houses), which may suggest
that cholinergic activity interacts with stimulus salience. The findings are discussed within the
context of the role of acetylcholine both in stimulus processing and stimulus salience, and in
establishing attention biases through top-down and bottom-up mechanisms of attention.
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INTRODUCTION
Selective attention constitutes the ability to discriminate significant or relevant stimuli from
irrelevant stimuli (ie noise) and to process information within our environment preferentially
(Desimone, 1998; Desimone and Duncan, 1995; Kastner and Pinsk, 2004; Moran and
Desimone, 1985). The need for such a selective process results from a limited attentional
capacity, so that the simultaneous presentation of multiple stimuli produces a competition
for representation at the neural level (Desimone, 1998; Kastner et al, 1998). Single-unit
recording studies (Chelazzi et al, 1998; Desimone, 1998; Reynolds et al, 1999) and
functional brain imaging studies (Beck and Kastner, 2005; Deco and Rolls, 2005; Kastner et
al, 1998) have demonstrated that the processing of a visual stimulus is influenced by the
presence of other, unattended visual stimuli, whereby neighboring stimuli interact to
produce suppressive effects on the processing of a target stimulus. The biased competition
model of selective attention suggests that this neural competition among multiple stimuli can
be mediated by two mechanisms that each contribute to the biasing of attention, including
‘bottom-up’ processes that act through stimulus-based operations, and ‘top-down’ processes
that act through cognitive or executive actions (Desimone, 1998; Duncan, 1998). Bottom-up
stimulus-based attentional mechanisms refer to neural processing that is biased by stimuli
with inherently salient or meaningful features, so that attention is captured automatically and
is associated with an enhancement of the neural representation of the stimulus. Inherent
stimulus salience may result from the presence of stimulus characteristics that produce
sensory salience (eg high contrast; unique color) (Egeth and Yantis, 1997; Parkhurst et al,
2002) or from the presence of stimuli that potentially have biological relevance (ie
behaviorally or socially) or environmental significance (Friesen et al, 2004; Ohman, 2005;
Parkhurst et al, 2002; Vuilleumier et al, 2001). In either case, attention is captured
automatically and is associated with an enhancement of the neural representation of the
stimulus. Top-down attentional mechanisms refer to knowledge-based processes where
attention is oriented intentionally, resulting in the enhancement of neural representations of
relevant, goal-directed stimuli and improved discrimination among competing stimuli based
on biases toward targets (Connor et al, 2004; Sarter et al, 2001). Bottom-up and top-down
mechanisms then interact (Corbetta and Shulman, 2002; Reynolds and Desimone, 2003;
Sarter et al, 2001) to result in a biased neural representation of a stimulus.
Human faces are socially important stimuli that convey critical information regarding the
environment. Evidence suggests that human faces capture attention or are given higher
priority than other types of objects (Bindemann et al, 2005; Ro et al, 2001; Vuilleumier,
2000) and may be processed automatically (Bredart et al, 2006; Lavie et al, 2003; Ohman,
2002; Palermo and Rhodes, 2006). Researchers have demonstrated that human faces
produce more interference when presented as distractor stimuli than do nonface objects
(Bindemann et al, 2005; Ro et al, 2001), and some have suggested that faces are difficult to
ignore due to their biological and social importance (Lavie et al, 2003). Together these
findings suggest that faces may be preferentially processed, perhaps through a combination
of bottom-up and top-down processes that bias neural processing in favor of faces.
The literature is rich with evidence of the involvement of the cholinergic system in attention
mechanisms (Everitt and Robbins, 1997; Hasselmo and McGaughy, 2004; Himmelheber et
al, 2000; Robbins, 1997; Sarter and Bruno, 2000; Sarter et al, 2003, 2005b; Yu and Dayan,
2002). Researchers have hypothesized that attentional processes are mediated through
cholinergic mechanisms that facilitate the processing of sensory information (Robbins,
1997) and some evidence exists to support this idea (Furey et al, 2000b; Sillito and Kemp,
1983a). Furthermore, evidence indicates that the cholinergic system is recruited through
both bottom-up, stimulus driven mechanisms and by top-down, goal-directed mechanisms
suggesting that cholinergic involvement in stimulus processing reflects the combined
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influence of both bottom-up and top-down attentional processes (reviewed by Sarter et al,
2005a).
In general, the cholinergic neurons of the basal forebrain that projects throughout neocortex
are thought to enhance signal-to-noise (S/N) ratios for neural processing (Murphy and
Sillito, 1991; Sato et al, 1987). Sillito (Sillito and Kemp, 1983b) demonstrated that the direct
application of acetylcholine to cat visual cortex increased the selectivity of the cell’s
response to stimulus orientation, consistent with the hypothesis that acetylcholine increases
S/N. Similarly, Buzsaki (1989) showed that cholinergic input to hippocampus is inhibitory,
suggesting that acetylcholine may enhance S/N in hippocampus by reducing the response to
noise. The cholinergic influence on S/N may constitute the neural mechanism through which
the cholinergic system influences selective attention, and may establish the relative strengths
of the neural representations of competing stimuli. For example, a functional imaging study
(Furey et al, 2000b) demonstrated that enhanced cholinergic activity selectively increased
neural responses to task-relevant stimuli (ie signal) with reduced or no change in neural
responses to task-irrelevant stimuli (ie noise), consistent with a selective enhancement for
target stimuli via S/N processing. The modulation of S/N processing in the context of the
neural representation of competing stimuli may alter the stimulus bias established between
attended and unattended stimuli.
The purpose of the current study was to evaluate the influence of cholinergic modulation on
behavioral performance of a selective attention task. The task required the alternation of
attention between two object categories present in each stimulus, thus the task required the
shifting of goal-directed attention between two competing stimuli. The two object categories
differed in the level of inherent salience (faces and houses), and thus as the task required the
shift in directed attention, the salience of the unattended stimulus changed. We expected that
acetylcholine is central to establishing the processing bias among competing stimuli. We
were interested specifically in evaluating the influence of cholinergic modulation on goal-
directed performance, and predicted that performance would change differentially
depending on the inherent salience of the unattended stimulus so that changes in
performance would reflect any shift in stimulus bias among the competing stimuli. A
stimulus category bias would be reflected by the difference in reaction times (RTs) when
attending to each of the two stimulus categories, and the larger this RT difference the greater
the bias toward the stimulus category with the fastest RT. Two separate studies were
conducted, one evaluating the enhancement of cholinergic activity using the
anticholinesterase and physostigmine, and the other investigating the inhibition of
cholinergic function using scopolamine.
EXPERIMENT 1: EFFECT OF ENHANCING CHOLINERGIC ACTIVITY ON
SELECTIVE ATTENTION
Methods
Subjects—Nine medically and psychiatrically healthy individuals (mean age ± SD = 31 ±
6 years; four females/five males) participated in a randomized, double-blind, placebo-
controlled crossover study. All participants gave written informed consent after the purpose
of the study and potential side effects of the drug were fully explained. The study was
approved by the National Institute on Aging Institutional Review Board (NIH protocol 00-
M-0056).
Experimental design—Subjects participated in two testing sessions, during which they
received in random order i.v. infusions of placebo or drug and subsequently performed the
selective attention task (see below). Participants received an infusion of physostigmine at a
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rate of 1.0 mg/h according to the following procedure: a 10-min loading dose of 1.93 mg/h
was used to quickly achieve the desired plasma levels followed by a maintenance drip of
0.816 mg/h to maintain stable drug levels to completion of the study session. Infusions
continued for 30 min before beginning the task to obtain stable drug effects (Furey et al,
2000a). Glycopyrrolate, which is a cholinergic muscarinic antagonist that does not cross the
blood–brain barrier, was administered i.v. (0.02 mg) before the physostigmine infusion to
minimize peripheral side effects (Mirakhur et al, 1977; Oduro, 1975). For the placebo
infusions, the same infusion schedule was used with saline. Blood pressure and
electrocardiogram (ECG) were monitored throughout each session for each subject.
Task design—Subjects performed a matching task while viewing two stimuli shown
simultaneously, side by side. In the selective attention task condition, two double-exposure
pictures of faces and houses were presented. Subjects were instructed by a cue to attend to
either the face or the house component of the stimuli, and to decide if the two exemplars
from the attended category were of the same person or house. Pictures with different views
of the same person or house were used, so that subjects could not base their response on a
simple pattern match. Subjects were cued to shift their attention from one stimulus
component to the other every 4–7 trials (see Figure 1a). Stimuli were presented for 2.5 s and
were followed by a 1.5 s intertrial interval. In the control task condition, two stimuli were
presented in the same spatial and temporal manner but here the double-exposure images
were phase scrambled to create stimuli that had equivalent luminance, contrast, and spatial
frequency spectra as the double-exposure pictures. The control condition required subjects
to determine if the scrambled images were the same or different. To control for the
presentation of the cue in the attention task, a cue comprised of one large and one small ‘x’
(ie X x) was presented between the two scrambled image stimuli. The cue changed every 4–
7 trials by switching the location of the large and small x (eg x X), with no relevance to task
requirements. Performance RT and accuracy were recorded.
Data analysis—Before analysis, any RT that was less than 800 ms was considered an
error and excluded from the data set, and any measure that exceeded three SDs above the
mean was excluded as an outlier. RT and accuracy data were analyzed using repeated
measures analysis of variance (ANOVA) under placebo conditions to characterize baseline
response features to the attentional target (faces vs houses) and the trial order (responses to
the first trial after a shift in attention to characterize performance associated with shifting
selective attention; and responses to subsequent trials to characterize performance associated
with the maintenance of selective attention, while subjects retain attention to one target
category). RT and accuracy associated with the maintenance of selective attention were
obtained by averaging response measures together across trials 1–4 before data analysis.
Trials 5–7 were not included, as these trials did not occur following every attention shift.
Drug effects were also analyzed by using repeated measures ANOVA so that drug condition
(placebo vs physostigmine), attention target, and trial were assessed. In the presence of
significant interactions or main effects, t-test comparisons were used to further characterize
these effects.
Results
Under placebo, RT showed a significant effect of attentional target (F = 16.5, p = 0.004),
where responses were slower when individuals attended to houses than when they attended
to faces. A significant effect of trial order also was observed (F = 10.15, p = 0.01), with
slower responses to trial 1 than to trials greater than 1. Accuracy data showed a significant
attentional target × trial order interaction under placebo conditions (F = 14.5, p = 0.005),
where accuracy was greater to the first trial vs later trials when attending to faces, but
accuracy was greater to later trials than to the first trial when attending to houses.
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Under physostigmine, a significant drug effect was present (F = 7.3, p = 0.027) indicating an
overall reduction in RT during drug (mean ± SD = 1755 ± 259) relative to placebo (1819 ±
256.7). A significant drug × trial order interaction also was observed (F = 5.3, p = 0.05)
showing that RT was reduced during physostigmine to a greater extent for later trials than
for trial 1 (Figure 2a), with t-tests demonstrating that no significant change in trial 1
occurred while a significant reduction was observed to trials greater than 1. A trend toward a
significant drug × attention interaction was seen (F = 4.01, p = 0.078; Figure 2b) with
reductions in RT when attending to houses (p = 0.009) but not when attending to faces (p =
0.60). Consistently, a significant drug condition × attention × trial order interaction also was
observed (F = 5.7, p = 0.04) (Figure 3), demonstrating that physostigmine decreased RT
differentially based on the attention conditions, relative to trial type. Specifically, within the
attention to faces condition, a significant drug × trial order interaction (F = 8.64, p = 0.002)
was present, showing that relative to placebo, physostigmine preferentially produced a
reduction in RT to later trials, consistent with the overall drug × trial order interaction
reported above. In contrast, within the attention to houses condition, a decrease in RT during
drug relative to placebo was evident (F = 21.54, p = 0.002), but no interaction with trial was
present (F = 0.2, p = 0.67), indicating that RT reductions occurred to all trials. No overall
drug effect on performance accuracy was observed (F = 0.01, p = 0.92). A trend toward a
drug × attention × trial order interaction was present (F = 4.0, p = 0.08), suggesting that the
attention × trial interaction seen under the placebo condition diminished under
physostigmine. No change in accuracy was seen in the later trials for either attention
condition.
No change (p = 0.30) in RT was observed to the control task during physostigmine (mean ±
SD = 1284 ± 275) relative to placebo (1267 ± 242).
Discussion
Cholinergic enhancement with physostigmine improved selective attention, but
preferentially enhanced performance during maintenance of selective attention as compared
to shifting the target of selective attention. This enhancement differed based on the attention
condition however, an effect that may be explained by cholinergic modulation of the relative
salience of competing stimuli.
‘Shift cost’ is a term that defines the behavioral cost associated with shifting attention from
one stimulus component to another, and is reflected by an increase in RT and decrease in
performance accuracy in association with the first trial following a shift in selective attention
relative to the subsequent trials (Monsell, 2003; Rogers and Monsell, 1995; Wylie and
Allport, 2000). This observation suggests that the cognitive requirements may differ at
different points in the task. Researchers have suggested that this response pattern develops
as a result of an incomplete cognitive reconfiguration, so that performance observed during
trial 1 occurs before a complete reconfiguration of the cognitive task set (Monsell, 2003;
Rogers and Monsell, 1995). The results reported here show that cholinergic enhancement
primarily influenced the maintenance of selective attention (ie trials greater than the first
trial after shifting attention) with less of an influence on shifting selective attention per se (ie
the first trial following a shift in selective attention). Our results may imply that the
cholinergic effect observed during trials greater than 1 is specific to performance that
follows the completion of cognitive reconfiguration, and is unrelated to the processes
involved in cognitive reconfiguration. The process of changing or shifting the task set thus
would be uninfluenced by cholinergic function.
Physostigmine also preferentially modulated performance during the attention to houses
condition, when faces were unattended and presumably producing interference to the
processing of houses (Bindemann et al, 2005; Lavie et al, 2003; Ro et al, 2001). From the
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perspective of the influence of unattended stimuli, faces are favored to grab attention and
produce interference over some other forms of stimuli, with the result that when stimuli are
competing for attention, a bias for faces exists (Bindemann et al, 2005). In the attention to
houses condition in the absence of cholinergic modulation, the face would produce
interference at the expense of the house while in the attention to face condition, the house
would not produce a similar level of interference. The current results suggest that the
enhancement of cholinergic activity may modulate the relative salience of the face and
house stimulus components so that the interference of the unattended face stimulus during
attention to houses is altered, producing a shift in the face bias with the result being that the
relative salience of the house stimulus is increased. Alternatively, the results may imply that
enhanced cholinergic activity may influence top-down mechanisms by improving the ability
to disengage attention or to ignore a salient stimulus that is not task related.
These results lead to clear hypotheses regarding the expected behavioral effects of inhibiting
cholinergic activity. Specifically, we expected that blocking cholinergic activity
preferentially would impair performance during the maintenance of selective attention as
opposed to the shifting of selective attention. Moreover, we hypothesized that the processing
bias toward faces observed at baseline would shift during scopolamine. During
physostigmine we observed a shift in the face bias resulting principally from improvement
in performance during attention to the unfavored house component of the stimulus.
Following cholinergic inhibition, we predicted a shift in the face bias resulting from
diminished selectivity for the favored face stimulus.
EXPERIMENT 2: EFFECT OF INHIBITING CHOLINERGIC ACTIVITY ON
SELECTIVE ATTENTION
Methods
Subjects—Thirty healthy individuals (mean age ± SD = 30 ± 7 years; 17 females/13
males) participated in a randomized, double-blind crossover study. All participants gave
written informed consent after the purpose of the study and potential side effects of the drug
were fully explained. The study was approved by the National Institute of Mental Health
Institutional Review Board.
Experimental design—Subjects participated in multiple testing sessions, during which
they received in random order i.v. infusions of placebo or drug and subsequently performed
the shifting selective attention task (see below). Participants received an infusion of
scopolamine at a dose of 0.04 μg/kg over a 15 min infusion period (Ebert et al, 2001).
Following completion of the infusion, a 45-min waiting period ensued to allow the peak
cognitive effects to develop and to allow the peak side effects (ie drowsiness) to diminish
(Safer and Allen, 1971). The same infusion and waiting periods were used with saline for
the placebo infusions. Blood pressure and ECG were monitored throughout each session for
each subject.
Task design—Subjects performed the matching task in the selective attention paradigm as
described above. In the control task (Figure 1b), two stimuli were presented in the same
spatial and temporal manner but images from each stimulus category were superimposed on
phase-scrambled images of the other category to create stimuli that had equivalent
luminance, contrast, and spatial frequency spectra as the double-exposure pictures. The
control condition required subjects to determine if the intact pictures were of the same
person or the same house. A cue was presented between the two stimuli that changed every
4–7 trials at which time the category of the intact component of the stimulus shifted.
Performance RT and accuracy were recorded.
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Data analysis—Statistical methods are as described for Experiment 1.
Results
Under placebo conditions, RT showed a significant effect of attention (F = 87.3, p<0.0001)
where RT was slower when individuals attended to houses than when they attended to faces,
and a significant effect of trial (F = 4.5, p = 0.044) with slower RTs associated with the first
trial following a shift in attention vs the subsequent trials. Accuracy data showed a trend
toward a trial effect (F = 3.2, p = 0.08) with accuracy tending to be higher to trials greater
than 1 relative to the first trial following a shift. No other effect was significant under
placebo conditions.
Under scopolamine, no overall drug effect on RT was present (F = 0.84, p = 0.37). A
significant drug × trial interaction was observed (F = 12.8, p = 0.001) with scopolamine
selectively increasing RT to trials greater than 1, with no change in the first trial following a
shift in attention (Figure 4a). As we hypothesized that scopolamine would modulate
performance preferentially during the attention to faces condition, we also performed
separate analyses on performance RT when attending to faces and houses, and found that RT
increased preferentially when attending to faces (F = 6.5, p = 0.02) with no significant effect
when attending to houses (F = 1.5, p = 0.24) (Figure 4b), although the drug × attention
interaction was not significant. There was no drug effect on performance accuracy, although
there was a trend for scopolamine to decrease accuracy overall (F = 2.8, p = 0.10).
Scopolamine effects on RT (p > 0.2) and accuracy (p > 0.2) did not differ based on gender.
Under placebo conditions in the control task, where stimulus conditions included intact faces
and houses superimposed on phase-scrambled pictures, there was no significant difference
in RT based upon trial (ie trial 1 vs trials greater than 1) (F = 0.31, p = 0.58) or based on the
attentional target (ie faces or houses) (F = 2.1, p = 0.13). A significant difference in
performance accuracy was observed based on attentional target (F = 11.7, p < 0.002), with
accuracy to houses being higher than accuracy to faces.
There was no significant overall effect of scopolamine on RT (F = 0.30, p = 0.59) in the
control task. A trend toward a drug × stimulus condition interaction (F = 3.0, p = 0.095) was
observed; in direct comparisons between placebo and scopolamine for each of the stimulus
conditions, a significant decrease in RT for house stimuli was seen during drug (F = 5.4, p =
0.02), while no change during face stimuli was observed (F = 0.01, p = 0.94) (Figure 5a).
There was no significant overall effect of scopolamine on performance accuracy (F = 1.6, p
= 0.29) during the control task. A drug × stimulus condition interaction was observed (F =
6.9, p = 0.01), and was explained by a selective reduction in accuracy during face trials,
while there was no change during house trials (F = 0.15, p = 0.67) (Figure 5b). A drug ×
stimulus condition × trial interaction (F = 7.8, p = 0.009) was also seen, demonstrating that
the selective reduction in accuracy observed during face trials (F = 28.1, p = 0.0001) was
larger to trial 1 than to trials greater than 1.
Performance on the attention task was compared to that on the control task to characterize
the specificity of the drug effects on selective attention. A significant drug × task interaction
was detected (F = 4.8, p = 0.04), that showed increased RT specifically to the selective
attention task, with no increase in the control task (Figure 5c). A significant drug × task ×
trial interaction (F = 6.0, p = 0.02) also was evident demonstrating that the larger increase in
RT during the selective attention task occurred preferentially during trials greater than 1. A
trend toward a drug × task × stimulus condition interaction was present (F = 3.4, p = 0.07)
due to the selective reduction in accuracy during trials with faces in the control task. No
other difference in the drug effect on the task conditions was seen.
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Post hoc analyses were also performed to compare directly the behavioral effects of
physostigmine and scopolamine. Thus drug condition (placebo and drug), attention, trial,
and drug group (physostigmine and scopolamine) were assessed in these analyses. A
significant drug condition × trial × drug group interaction was found (F = 10.31, p = 0.003),
and demonstrated that the drug effects were largest for later trials (vs trial 1), where
scopolamine increased and physostigmine decreased RT. This result is summarized in
Figure 6a where the difference between RT during placebo and drug is shown for trial 1 and
for trials greater than 1, for both physostigmine and scopolamine. The differential effects of
physostigmine and scopolamine on the attention conditions are shown in Figure 6b where
the difference between RT during placebo and drug is shown during attention to faces and
houses. Scopolamine increases RT, with significant increases seen only during attention to
faces; physostigmine decreases RT, with significant reductions seen only during attention to
houses. The drug condition × attention × drug group interaction was not significant, but a
significant drug condition × attention × trial × drug group interaction was seen (F = 4.0, p =
0.05).
Discussion
The results from this study suggest that cholinergic modulation preferentially influences
maintenance of selective attention, with little influence on the shifting of attention.
Enhancing cholinergic function using physostigmine improved task performance primarily
in trials beyond the first trial following a shift in attention, suggesting that the effects were
predominantly associated with maintenance of selective attention. Parallel to the
physostigmine result, inhibiting cholinergic function using scopolamine impaired
performance primarily in trials associated with maintenance of selective attention. Together
these findings provide complementary data showing that cholinergic function is related
preferentially with the maintenance of selective attention, after task-set reconfiguration has
taken place (Monsell, 2003), rather than during the shifting of attention per se.
Our findings also support the hypothesis that manipulation of cholinergic activity modulates
the relative salience of competing stimuli during selective attention to result in specific and
selective effects on performance. Further, our results support the hypothesis that the
cholinergic system, which is instrumental in the perceptual processing of stimuli, contributes
to establishing stimulus biases at a neural level based on the interaction between stimulus-
driven and goal-directed mechanisms that modulate the representation of competing stimuli.
Under both conditions of cholinergic modulation, the bias toward face processing observed
under placebo was diminished during drug, as indicated by a reduction in the differences
between the RT when attending to faces and when attending to houses. The face bias was
diminished during physostigmine by improving performance primarily when attending to
the less favored stimulus (ie houses), rendering the performance during the two attention
conditions more similar. In contrast, the face processing bias was diminished during
scopolamine by reducing performance primarily when attending to the favored stimulus (ie
faces), again rendering performance during the two attention conditions more similar.
Previously we provided an alternative interpretation of the physostigmine results, suggesting
that enhanced cholinergic activity may act exclusively through top-down attention control
mechanisms, and improve the ability to disengage attention or to ignore a salient stimulus
that is not task related. The scopolamine results would argue against this interpretation. If
enhancing cholinergic activity improved the ability to ignore a salient stimulus (ie faces)
through improved top-down effects, then we would expect that impairing cholinergic
activity would diminish top-down abilities. This may present as a reduced ability to
disengage attention, thus producing a generalized impairment in performance, or this may
present as a reduced ability to ignore salient stimuli resulting in an increase in the processing
bias toward faces, with RT primarily increasing during attention to houses. Instead, we see a
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selective reduction in the face bias, with a decrease in the face preference indicated by
preferential increases in RT when attending to faces. The results together support the
interpretation that acetylcholine influences stimulus processing through interactions between
stimulus-driven and goal-directed mechanisms to produce a relative salience among the
competing stimuli.
In the current studies under placebo conditions, a bias toward processing faces over houses
was evident, as RT was faster during attention to faces than attention to houses. Conceivably
this bias could be due to the manner in which the stimuli were developed, inadvertently
resulting in the faces being easier to discriminate. However, the selectivity of the
physostigmine effect, showing a preference for enhanced processing of the attended
stimulus during attention to houses, suggests that the original bias is face specific and not
due to an unintentional bias that resulted from the manner in which the stimuli were created.
Similarly, the influence of acetylcholine on the face bias under placebo conditions also is
diminished during scopolamine, as evidenced by changes in performance preferentially
during the attention to faces condition. Again, the selectivity of the effect to the attention to
faces condition argues against the interpretation that the behavioral response pattern is due
to faces being easier to discriminate before drug administration. One would expect
scopolamine to produce similar impairment in both attention conditions if there was no
stimulus selectivity associated with these effects. Moreover, an attentional bias toward faces
has been described by others, as demonstrated by the difficulty associated with the
disengagement of processing resources from face stimuli (Bindemann et al, 2005) or the
advantage that faces retain over other types of objects to capture attention (Ro et al, 2001;
Vuilleumier, 2000). Finally, in the event that the original, baseline category bias was
influenced by the manner in which the stimuli were developed, this would have little
influence on the interpretation of the data. Specifically, the behavioral effects discussed in
this paper are in the context of the direction and manner of response change from baseline
following cholinergic modulation, and this behavioral change is interpreted in the context of
stimulus bias.
Importantly, no overall effect of scopolamine on RT was observed. The effects we obtained
were selective to task conditions, reflecting effects on stimulus processing speed, and were
not attributable to nonspecific impairments in task performance.
The control task also provided critical information regarding the specificity of our findings.
Again, no overall effect of scopolamine on RT or on accuracy was observed during
performance of the control task. A selective reduction in performance accuracy was
observed to faces, with no change in accuracy to trials with houses. In addition, we
identified a decrease in RT during scopolamine specifically to the house stimuli, a result that
further highlights both the selectivity of our findings to the selective attention condition as
well as the absence of a generalized effect on performance. A similar specificity was
observed during physostigmine, where RT reductions were selective to task conditions, with
no effect observed during the control condition.
The basal forebrain cholinergic neurons release acetylcholine in response to target stimuli
under conditions of directed attention and to inherently salient stimuli that automatically
draw attention (Sarter et al, 2005a). The effect of cholinergic modulation on the processing
of each competing stimulus during a selective attention task would depend on the relative
influence of acetylcholine on these two interacting components. Evidence suggests that
acetylcholine does influence both mechanisms (Sarter et al, 2005a), but the relative
influence is not clear. Our findings are consistent with the interpretation that acetylcholine
alters the relative salience of the signal (ie attended stimulus) and noise (ie unattended
stimulus).
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Together, these findings support the hypothesis that acetylcholine influences both stimulus-
driven and task-directed attentional mechanisms in an interactive way. Moreover, this
framework merges well with the biased competition model of attention (Desimone, 1998;
Reynolds et al, 1999), supporting the hypothesis that cholinergic activity influences
stimulus-driven and task-directed attentional processing to establish biases among
competing stimuli.
The effort to determine specifically which cholinergic receptor(s) mediates these behavioral
effects is limited as a result of the mechanism of action of physostigmine. As an
anticholinesterase inhibitor, physostigmine acts by inhibiting the breakdown of
endogenously released acetylcholine present in the synapse. As a result, we are unable to
determine directly whether physostigmine is acting through muscarinic or nicotinic receptor
sites to produce the observed results. Because scopolamine interacts selectively with
muscarinic receptors, we can attribute the behavioral effects on attention observed during
scopolamine to muscarinic receptor antagonism. Moreover, that the behavioral effects of
physostigmine and scopolamine observed in the context of this study are highly
complementary, one might hypothesize that during this attention task, physostigmine is
influencing cholinergic activity primarily at muscarinic receptor sites. Despite the fact that
physostigmine is nonselective for receptor type, the nature of an anticholinesterase inhibitor
is to enhance naturally released acetylcholine, so that the effects of the acetylcholine
released while performing the selective attention task are bolstered. One could argue that we
know muscarinic receptors are involved in performing this task based on the scopolamine
results, and therefore conclude that physostigmine at least partly acts through muscarinic
sites but may implicate nicotinic sites as well.
Interactions between estrogen and the cholinergic system (Granholm, 2000; Tinkler et al,
2004) are known to modulate cognition functions including attention (Granholm et al, 2002;
Tinkler and Voytko, 2005; Voytko, 2002). In our post hoc analyses, we observed no
difference in the behavioral response to scopolamine based on gender.
The results as reported here in the context of selective attention may be more specific to
selective attention when face stimuli are involved. Evidence indicates that faces retain a
unique ability to gain attention (Bindemann et al, 2005; Lavie et al, 2003; Ro et al, 2001),
and in this regard the effects we have reported here may be specific to face stimuli.
These results suggest that acetylcholine contributes at multiple levels to the mechanisms
underlying selective attention. The preferential influence on performance during later trials
following a shift in attention during both physostigmine and scopolamine indicates that
acetylcholine is more central to the maintenance of selective attention and less implicated in
the shift in attention per se. The results also suggest that acetylcholine may influence
selective attention via S/N mechanisms that contribute to establishing relative salience
among competing stimuli.
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Figure 1.
The selective attention task.
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Figure 2.
The effects of drug on mean RTs (+ SE) are shown for trial order (trial 1 vs subsequent
trials) in (a) and for selective attention (faces vs houses) in (b). Performance during placebo
is indicated in red and during physostigmine in blue. The p-values indicate level of
significance for the identified interactions and for the within condition drug effects.
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Figure 3.
Mean RTs (+SE) characterizing the drug × attention condition by trial order interaction, with
performance during placebo in red and during physostigmine in blue.
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Figure 4.
The effects of drug on mean RTs (+ SE) are shown for trial order (trial 1 vs subsequent
trials) in (a) and for selective attention (faces vs houses) in (b). Performance during placebo
is indicated in red and during scopolamine in yellow. The p-values indicate level of
significance for the indicated interactions and for the within condition drug effects.
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Figure 5.
The effects of drug on mean RT (±SE) (a) and performance accuracy (b) during the control
task are shown, separated for trials with faces and trials with houses on phase-scrambled
backgrounds. Performance during placebo is indicated in red and during scopolamine in
yellow. The p-values indicate level of significance for the indicated interactions and for the
within condition drug effects.
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Figure 6.
The mean changes in RTs (+ SE) on drug as compared to placebo are shown for
scopolamine in yellow and for physostigmine in blue. The differential effects of drug
(scopolamine vs physostigmine) are shown for trial order (a) and for selective attention (b).
As drug effects primarily are found in trails subsequent to trial 1, only these trials are
included when assessing the effects of drug on selective attention (b).
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